一、停复牌 嘉事堂：股东光大实业筹划公司股权转让，股票停牌。 二、回购 片仔癀：控股股东九龙江集团拟3亿元-5亿元增持公司股份。创新药PZH2113胶囊Ⅰ期临床试验完成首 例受试者入组，国内外暂无相同适应症的同靶点药品获批上市。 三、并购重组 泰凌微：拟通过发行股份及支付现金方式收购磐启微100%股权。 四、经营 1、百通能源：拟通过全资子公司图达铝业与安哥拉共和国丹德港发展有限公司签订《投资意向协 议》，拟以自有及自筹资金约4亿美元对外投资，并设立全资公司百通图达（安哥拉）铝业有限公司。 2、普洛药业：与杭州德睿智药科技有限公司签订《战略合作框架协议》，开展CDMO项目的长期合 作。 3、诺德股份：拟对全资子公司青海电子2010年投资建设的二厂1.5万吨生产线设备实施更新改造，项目 总投资估算为人民币1.68亿元；改造完成后，生产范围将从原有设计规格为6-8微米及以上常规锂电铜 箔，拓展至具备4.5微米及以下高端锂电铜箔的量产能力。 五、业绩变动 1、国泰海通：2025年净利润为275.33亿元至280.06亿元，同比增加111%至115%。财富管理、机构与交 易等业务收入同比显著增长。 6、南亚新材：20 ...

(本文来自第一财经) 嘉事堂公告，公司于2026年1月27日接到股东中国光大实业（集团）有限责任公司书面通知，光大实业 及子公司中国光大医疗健康产业有限公司正在筹划公司股权转让事宜，该事项可能导致公司控股股东、 实际控制人发生变更。公司股票自2026年1月28日开市起停牌，预计停牌时间不超过2个交易日。 ...

证券代码：002462 证券简称：嘉事堂 公告编号： 2026-02 嘉事堂药业股份有限公司 关于筹划控制权变更事项的停牌公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司股票于 2026 年 1 月 28 日（星期三）开市起停牌，预计停牌时间不 超过 2 个交易日。 2、本次交易事项目前尚存在重大不确定性，敬请广大投资者注意投资风险。 特此公告。 嘉事堂药业股份有限公司 董 事 会 2026 年 1 月 28 日 嘉事堂药业股份有限公司（以下简称"公司"）于 2026 年 1 月 27 日接到股 东中国光大实业（集团）有限责任公司（以下简称"光大实业"）书面通知， 光大实业及子公司中国光大医疗健康产业有限公司正在筹划公司股权转让事宜， 该事项可能导致公司控股股东、实际控制人发生变更。 鉴于本次交易事项目前尚存在不确定性，为保证公平信息披露、维护公司 全体股东利益，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公 司自律监管指引第 ...

Group 1 - The core viewpoint of the news is that 嘉事堂's stock has experienced fluctuations, with a recent decline of 2.02% and a current price of 16.50 yuan per share, while the company has seen a year-to-date increase of 14.90% [1] - As of January 9, 嘉事堂's shareholder count has increased by 50% to 36,000, while the average circulating shares per person decreased by 33.33% to 8,096 shares [2] - 嘉事堂's main business involves pharmaceutical wholesale and retail, with commercial revenue accounting for 100% of its income [1] Group 2 - For the period from January to September 2025, 嘉事堂 reported a revenue of 14.459 billion yuan, representing a year-on-year decrease of 21.80%, and a net profit attributable to shareholders of 141 million yuan, down 38.81% year-on-year [2] - 嘉事堂 has been listed on the stock market since August 18, 2010, and has distributed a total of 874 million yuan in dividends since its A-share listing, with 216 million yuan distributed in the last three years [2] - The company operates within the pharmaceutical and biological industry, specifically in the pharmaceutical commercial sector, and is involved in various concept sectors including pharmaceutical e-commerce and state-owned enterprise reform [2]

证券之星消息，1月22日医药商业板块较上一交易日上涨0.94%，华人健康领涨。当日上证指数报收于 4122.58，上涨0.14%。深证成指报收于14327.05，上涨0.5%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301408 | 华人健康 | 23.17 | 6.24% | 34.71万 | | 7.81亿 | | 301017 | 激玉平民 | 17.71 | 4.67% | 18.88万 | | 3.28亿 | | 002462 | 幕事堂 | 16.89 | 4.65% | C 20.59万 | | 3.44亿 | | 002788 | 醫症医药 | 16.75 | 3.14% | 47.30万 | | 7.83亿 | | 301126 | 达嘉维康 | 13.92 | 3.11% | 15.80万 | | 2.19亿 | | 600272 | 开开实业 | 14.56 | 2.46% | 6.88万 | | 9913.17万 | ...

Group 1 - The core viewpoint of the news is that 嘉事堂's stock has experienced fluctuations, with a recent decline of 2.02% and a total market value of 4.673 billion yuan [1] - As of January 9, 嘉事堂's shareholder count increased by 50% to 36,000, while the average circulating shares per person decreased by 33.33% to 8,096 shares [2] - 嘉事堂's stock price has risen by 11.56% year-to-date, but it has seen a slight decline of 0.56% over the past five trading days [1] Group 2 - 嘉事堂's main business involves pharmaceutical wholesale and retail, with commercial revenue accounting for 100% of its income [1] - For the period from January to September 2025, 嘉事堂 reported a revenue of 14.459 billion yuan, a year-on-year decrease of 21.80%, and a net profit attributable to shareholders of 141 million yuan, down 38.81% year-on-year [2] - Since its A-share listing, 嘉事堂 has distributed a total of 874 million yuan in dividends, with 216 million yuan distributed over the past three years [3]

Group 1 - The company, Jia Shi Tang (002462), has over 36,000 shareholders as of January 9, 2026 [1]

Market Performance - The pharmaceutical commercial sector increased by 0.8% on January 12, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] Top Gainers - RunDa Medical (603108) closed at 19.47, up 8.53%, with a trading volume of 1.0956 million shares and a transaction value of 2.123 billion [1] - Jia Shi Tang (002462) closed at 17.13, up 6.33%, with a trading volume of 441,200 shares and a transaction value of 733 million [1] - Yao Yi Gou (300937) closed at 38.42, up 4.54%, with a trading volume of 127,500 shares and a transaction value of 480 million [1] Top Losers - Nanjing Pharmaceutical (600713) closed at 5.43, down 1.63%, with a trading volume of 284,200 shares and a transaction value of 154 million [2] - Zhong Yao Holdings (000950) closed at 6.24, down 1.11%, with a trading volume of 740,900 shares and a transaction value of 461 million [2] - Ying Te Group (000411) closed at 12.81, down 1.08%, with a trading volume of 187,000 shares and a transaction value of 239 million [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 234 million from institutional investors and 184 million from speculative funds, while retail investors saw a net inflow of 417 million [2] - RunDa Medical had a net inflow of 123 million from institutional investors, but a net outflow of 171 million from speculative funds [3] - Jia Shi Tang experienced a net inflow of 80.845 million from institutional investors, with a net outflow of 28.7836 million from speculative funds [3]

Group 1 - The core viewpoint of the news is that 嘉事堂's stock has shown a significant increase in price and trading activity, with a year-to-date increase of 14.76% and a recent 2.30% rise on January 12 [1] - As of January 12, 嘉事堂's stock price is 16.48 yuan per share, with a total market capitalization of 4.807 billion yuan and a trading volume of 373 million yuan [1] - The company has experienced net outflows of main funds amounting to 13.048 million yuan, with large orders showing a buy of 68.0275 million yuan and a sell of 76.7042 million yuan [1] Group 2 - 嘉事堂's main business involves pharmaceutical wholesale and retail, with commercial revenue accounting for 100% of its income [1] - The company is classified under the pharmaceutical and biological industry, specifically in the pharmaceutical commercial sector, and is associated with concepts such as medical devices and pharmaceutical e-commerce [2] - As of December 19, 嘉事堂 has 24,000 shareholders, an increase of 9.09%, with an average of 12,144 circulating shares per shareholder, a decrease of 8.33% [2] Group 3 - 嘉事堂 has distributed a total of 874 million yuan in dividends since its A-share listing, with 216 million yuan distributed over the past three years [3] Group 4 - For the period from January to September 2025, 嘉事堂 reported a revenue of 14.459 billion yuan, a year-on-year decrease of 21.80%, and a net profit attributable to shareholders of 141 million yuan, down 38.81% year-on-year [2]

周五，嘉事堂股价低开低走，报收于16.11元。盘后数据显示，因日跌幅偏离值达到7%而上榜。 买入方面，东方财富证券拉萨团结路第二营业部买入884.48万元，同时卖出460.47万元。东方财富证券 拉萨东环路第二营业部买入695.68万元，卖出736.27万元。这两家被市场视为散户大本营的席位均出现 在买方前列。此外，一家机构专用席位买入642.07万元，华泰证券常州和平北路营业部买入606.87万 元，华西证券成都龙腾东路营业部买入564.74万元。 卖出方面，机构席位成为抛售主力。四家机构专用席位分别卖出1687.12万元、1401.17万元、1324.77万 元和1270.31万元，合计卖出金额超过5600万元。联储证券宁波分公司卖出1166.22万元。 从阶段性表现看，嘉事堂自1月5日启动以来，期间最高价曾触及19.69元。 风险提示：以上信息基于公开数据整理，不构成任何投资建议。股市有风险，入市需谨慎。（本内容由 AI基于交易所公开数据整理生成，仅供参考，不构成投资建议。） 本文源自：市场资讯 作者：智投君 ...